Kamila Akzholova

Ms. Kamila Akzholova

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MBMakhabbat Bekbossynova Bekbossynova
Makhabbat Bekbossynova Bekbossynova
TITatyana Ivanova-Razumova
Tatyana Ivanova-Razumova
AKAknur Kali
Aknur Kali
ASAliya Sailybayeva Sailybayeva
Aliya Sailybayeva Sailybayeva
SKSadyk Khamitov
Sadyk Khamitov
TSTimur Saliev
Timur Saliev
Background: Apolipoprotein B (ApoB), a key component of atherogenic lipoproteins, has been increasingly implicated in cardiometabolic disorders beyond dyslipidemia. However, its role in glycemic dysregulation remains unclear. This study aimed to investigate the association between ApoB levels and glycemic parameters, including fasting glucose, insulin resistance, and glycated hemoglobin (HbA1c), in individuals without diagnosed diabetes. Methods: This study was conducted at the National Research Cardiac Surgery Center (Kazakhstan) over the period between 2023 and 2024 as a cross-sectional analysis. Adults aged ≥ 20 years without diagnosed diabetes and with complete data on their ApoB and glycemic markers were included. Associations between ApoB and fasting plasma glucose (FPG), HbA1c, and HOMA-IR were assessed using multivariable linear and logistic regression models adjusted for demographic, lifestyle, and metabolic covariates. Results: Higher ApoB levels were significantly associated with increased fasting glucose (β = 2.07 mg/dL per 1-SD increase in ApoB, p < 0.001), higher HbA1c (β = 0.06%, p < 0.001), and elevated HOMA-IR (β = 0.54, p < 0.001). Participants in the highest ApoB quartile had 53% higher odds of prediabetes (adjusted OR = 1.53; 95% CI: 1.22–1.91; p < 0.001) compared to the lowest quartile. These associations remained significant after adjusting for BMI, lipid levels, and other confounders. Conclusions: Elevated ApoB is independently associated with adverse glycemic profiles in nondiabetic individuals, suggesting its potential role in early glucose metabolism disturbances.

17 May 2025 in Epidemiology and Health Data Insights
Verified
Journal Article
Open access
PDF file
AYArtem Yermakov
Artem Yermakov
KAKamila Akzholova
Kamila Akzholova
TATemirgali Aimyshev
Temirgali Aimyshev
IAIliyar Arupzhanov
Iliyar Arupzhanov
GZGulnur Zhakhina
Gulnur Zhakhina
AGAbduzhappar Gaipov
Abduzhappar Gaipov
Aim: To examine all-cause mortality predictors among lab indicators and drugs administered to stroke patients in Kazakhstan. Methods: This retrospective study analyzed data from 272 patient records derived from the UNEHS database (2014-2019). The GPT-4o model was used to dissect the records and assist in the extraction of lab and medication data; other clinical and demographic data were derived from the previous study [6]. Statistical analyses included univariate, multivariate, and imputed multivariate logistic regressions (STATA version 16.1). Results: In our cohort, deceased patients were older (66.1 vs. 58.6, p < 0.0001). Adjusted logistic regression revealed age (OR 1.04), hemoglobin (OR 0.97), and piracetam (OR 3.17) as independent predictors. After multiple imputation, Russian ethnicity (OR 2.79), PTI (OR 0.97), and dopamine (OR 5.23) became independent predictors, while piracetam lost its significance. Conclusions: Findings suggest the importance of future research on stroke predictors in bigger cohorts to facilitate the introduction of innovations to stroke patients’ care to potentially decrease the burden on the Kazakhstani population.

20 March 2025 in Journal of Health Development
Verified
Journal Article
Open access
BOBolat Ospanov
Bolat Ospanov
ATAskhat Tasbulatov
Askhat Tasbulatov
KAKamila Akzholova
Kamila Akzholova
Collaborative care involving family members and medical staff in intensive care is becoming an increasingly important topic in modern medicine. Studies indicate that the active participation of close relatives in the care process not only contributes to faster recovery but also enhances the psychological resilience of patients, creating a supportive environment that is crucial for effective healing. Understanding and utilizing this synergy can significantly improve treatment effectiveness and reduce the burden on healthcare providers by promoting a holistic approach to patient care.Objective: To determine the impact of collaborative care involving family members and medical staff on the recovery speed of patients in intensive care, assess factors that contribute to successful rehabilitation, and identify ways to integrate these practices systematically for improved patient outcomes.We conducted a systematic literature review to examine and assess the role of collaborative care between family members and medical staff in cardiopulmonary resuscitation and assess its impact on patient recovery speed. Research was sourced from databases including the Cochrane Library, Medline, and EMBASE. The studies included span until January 2023 and comprise several systematic reviews, meta-analyses, and randomized controlled trials (RCTs) that investigate the impact of collaborative care on patient recovery in intensive care units, particularly in cardiopulmonary resuscitation.Conclusions. The results of this review indicate that patients receiving collaborative care from family members and medical staff experience faster recovery and shorter ICU stays. Key factors influencing these positive outcomes include the provision of emotional support from relatives, which bolsters patient morale, and the coordinated actions of medical personnel, which ensure continuity and comprehensiveness in care delivery. These findings underscore the importance of structured family involvement and highlight the need for policies that support collaborative practices in intensive care settings to optimize patient outcomes and foster a more compassionate care experience.

14 November 2024 in Наука и здравоохранение
Verified
Journal Article
Open access
ASAliya Sailybayeva
Aliya Sailybayeva
TITatyana Ivanova-Razumova
Tatyana Ivanova-Razumova
KAKali A.
Kali A.
SKSadyk Khamitov
Sadyk Khamitov
GGGulnur Gulnur
Gulnur Gulnur
KAKamila Akzholova
Kamila Akzholova
Introduction. Established in 2021, the Lipid Clinic Network of Kazakhstan is dedicated to creating a global framework for consistent standards in diagnosing, managing, and treating lipid disorders, guided by the European Society of Cardiology and European Atherosclerosis Society (further - ESC/EAS) Guidelines on dyslipidaemia management. The aim is to evaluate pillars for LCN in Kazakhstan and assess the feasibility of dyslipidemia clinics and implementation atherosclerosis project in Kazakhstan. Materials and methods. This is a cross-sectional survey with 8 questions to explore the organization of a lipid clinic network in Kazakhstan. 28 clinics took part and respondents were anonymous. The questionnaire was based on EAS LCN evaluation. Results. 54 % of dyslipidemia clinics are located in outpatient department and 11% of clinics are located as a sub-department within a cardiology department or similar in the hospital. 71% of clinics (20) show connections to hospital departments including diabetes, endocrinology and rare disease units. The staff composition of LCN Kazakhstan is: physicians - 26, nurses - 20, geneticist expert in dyslipidemias’ - 1, dietitian – 4, nutritionist - 0. A majority of clinics (53.60%) are situated in outpatient departments, highlighting a prevalent reliance on outpatient care for lipid-related services. The physician and nurse staffing levels align with LCN-EAS standards, the lack of nutritionists, geneticists, and dietitians represents a significant gap in the multidisciplinary care model advocated by the EAS. Capacity to provide therapeutic education on lifestyle changes, cardiovascular disease (CVD) prevention, and adherence to treatment is present in 16 clinics. Conclusion. Some criteria of LCN Kazakhstan are aligned with EAS LCN requirements in terms of data management, location, facility and the, management of the interaction with the patients. However, composition of staff, clinical trial management and connection within the health service infrastructure and patient referral need to be enhanced. Введение: Липидная Клиническая Сеть (далее – ЛКС) Казахстана, созданная в 2021 году, посвящена созданию глобальной структуры для стандартизированного подхода к диагностике, управлению и лечению липидных нарушений, руководствуясь рекомендациями Европейского общества кардиологии и Европейского общества атеросклероза (далее – ЕОК/ЕОА) по управлению дислипидемией. Цель. Оценка основных направлений Липидной клинической сети Казахстана и оценка осуществимости работы клиник по лечению дислипидемий и реализации проекта по атеросклерозу в Казахстане. Материалы и методы: Исследование было выполнено методом поперечного опроса, состоящего из 8 вопросов, направленных на изучение организации сети липидных клиник в Казахстане. В исследовании приняли участие 28 клиник, респонденты опроса были анонимными. Анкета была разработана на основе оценки ЛКС Европейского общества атеросклероза. Результаты: 54% клиник дислипидемии расположены в амбулаторных отделениях, и 11% клиник функционируют в качестве подотделов в кардиологических отделениях или аналогичных подразделениях больниц. 71% клиник (20) демонстрируют связь с больничными отделениями, такими как диабетология, эндокринология и отделения редких заболеваний. Согласно результатам опроса, персонал ЛКС Казахстана распределен следующим образом: врачи – 26, медсестры – 20, специалист по генетике дислипидемий – 1, диетолог – 4, нутриционистов нет. Значительное большинство клиник (53,60%) расположено в амбулаторных отделениях, что подчеркивает зависимость от амбулаторной помощи в предоставлении липидных услуг. Количество врачей и медсестер соответствует стандартам ЛКС-ЕОА, однако нехватка нутриционистов, генетиков и диетологов представляет значительный пробел в многопрофильной модели ухода, рекомендованной ЕОА. Возможность предоставить терапевтическое обучение по изменению образа жизни, профилактике сердечно-сосудистых заболеваний (ССЗ) и соблюдению режима лечения присутствует в 57% клиник. Заключение: Некоторые критерии ЛКС Казахстана соответствуют требованиям ЕОА в части управления данными, местоположения, инфраструктуры и взаимодействия с пациентами. Однако...

28 December 2024 in Journal of Health Development
Verified
Journal Article
Open access
PDF file
GGGulnur Gulnur
Gulnur Gulnur
AAAruzhan Asanova
Aruzhan Asanova
ABAidos Bolatov
Aidos Bolatov
VSVitaliy Sazonov
Vitaliy Sazonov
YPYuriy Pya
Yuriy Pya
KAKamila Akzholova
Kamila Akzholova
Кіріспе. Соңғы 50 жылда трансплантация әлемде кеңінен табысты практикаға айналды. Алайда, елдер арасында донорлық органдарға қол жетімділік, сондай-ақ адам жасушалары, тіндері мен органдарын донорлау және трансплантациялау қауіпсіздігі, сапасы және тиімділігінде айтарлықтай айырмашылықтар бар. Мақсаттар. Осы шолудың мақсаты — Қазақстандағы орган трансплантациясының мәселелерін әлемдік контексте анықтау. Әдістер. Іздеу электронды дерекқорларды пайдалана отырып жүргізілді, әсіресе PubMed, Google Scholar, Medline және Scopus. Айқындаған зерттеулердің тақырыптары мен аннотациялары таңдалды, толық мәтінді мақалалар сәйкестік үшін қаралды. Іздеуде келесі кілт сөздер қолданылды: қатты органдар трансплантациясы, трансплантациядағы этика, органдарды сақтау және трансплантация мәселелері. Іздеу тереңдігі — 10 жыл. Нәтижелер мен қорытындылар. Орган донорлығына тән ерекшеліктер бірнеше күрделі моральдық, этикалық және құқықтық мәселелерді шешуді қажет етеді, себебі бұл өмір мен өлім арасындағы шекарада орналасып, қайтыс болған және тірі адамдардың мүдделерін қамтиды. Осы контексте, медициналық қауымдастықтың, әсіресе қарқынды терапия бөлімшелерінің қызметкерлерінің орган донорлығына қатысты көзқарасын өзгерту Қазақстанда трансплантацияның дамуы үшін маңызды. Кілт сөздер: Орган трансплантациясы, тірі донорлар, трансплантат алушылар, органдарды сақтау шешімдері, трансплантациядағы этика.

30 June 2025 in BULLETIN OF SURGERY IN KAZAKHSTAN
Verified
Journal Article
Closed access
ASAliya Sailybayeva
Aliya Sailybayeva
MGMyrzakhmetova G
Myrzakhmetova G
SSSeitkasym S
Seitkasym S
SASailybaeva A
Sailybaeva A
KSKhamitov S
Khamitov S
KAKamila Akzholova
Kamila Akzholova
Background. Metabolically associated fatty liver disease is closely linked to dyslipidemia and cardiovascular disease but the role of triglycerides as predictors of metabolically associated fatty liver disease severity remains underexplored. Purpose. This study aimed to evaluate the association between triglyceride levels and hepatic steatosis and fibrosis in patients at high cardiovascular risk. Methods. A total of 284 patients with cardiovascular disease and suspected metabolically associated fatty liver disease underwent clinical evaluation, lipid profiling, and non-invasive liver assessment via Fibroscan. Spearman correlation analysis was used to explore relationships between triglycerides, liver steatosis, fibrosis, and lipid parameters. Results. Triglycerides showed a modest positive correlation with hepatic steatosis (r = 0.27) and a weaker correlation with fibrosis (r = 0.11). Additionally, triglycerides correlated moderately with total cholesterol (r = 0.36) and low-density lipoprotein cholesterol (r = 0.35). No significant sex differences in liver disease stages were found. Conclusion. Triglycerides may serve as accessible biomarkers for early metabolically associated fatty liver disease related liver changes in cardiovascular patients. Further research is needed to validate their clinical utility.